Kristin Anderson, MD
Medical Oncology · San Diego, CANPI 1962732354
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $236 of the $376 with a category attached, or 62.7%. 9 manufacturers reported payments, led by Bristol Myers Squibb at 37.0% of the total. 2025 is the largest year on record at $115, 4.0 times the $29 reported in 2019. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 22 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$139
- Pfizer$117
- Medtronic$35
- Boehringer Ingelheim$16
- AbbVie$16
- Boston Scientific$16
- plus $36 from 3 others
Across 70 payments — averaging $10,867 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$390K
- E.r. Squibb & Sons, L.L.C.$122K
- Tolmar, Inc.$101K
- Genentech, Inc.$45K
- Astrazeneca UK Limited$41K
- Eli Lilly$35K
- plus $27K from 3 others
What the payments were for
- Food & beverage$23663%
- Education$14037%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 8 | $139 |
| Pfizer | 7 | $117 |
| Medtronic | 1 | $35 |
| Boehringer Ingelheim | 1 | $16 |
| AbbVie | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Tempus AI, Inc | 1 | $14 |
| Gilead | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$376 in reported general payments places this provider in the 25th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 35 | $755,625 |
| RevlimidLenalidomide | 40 | $754,591 |
| JakafiRuxolitinib Phosphate | 14 | $244,045 |
| SprycelDasatinib | 12 | $208,429 |
| XtandiEnzalutamide | 12 | $172,173 |
| TavalisseFostamatinib Disodium | 11 | $164,033 |
| KisqaliRibociclib Succinate | 12 | $136,249 |
| VenclextaVenetoclax | 27 | $110,790 |
| EliquisApixaban | 49 | $31,989 |
| Exemestane | 35 | $2,629 |
| Letrozole | 105 | $2,387 |
| Hydroxyurea | 72 | $2,091 |
| Tamoxifen Citrate | 63 | $1,306 |
| Acyclovir | 48 | $1,111 |
| Dexamethasone | 42 | $815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $139 | $754,59140 claims |
| AbbVieVenclexta | $16 | $110,79027 claims |
| PfizerEliquis | $117 | $31,98949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 379 medical oncology providers in California.
Other medical oncology in San Diego
- April TeitelbaumSan Diego$1.1M
- Marin XavierSan Diego$919K
- Klaus WagnerSan Diego$119K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.